After rising over $100 briefly this year, Cassava Sciences (NASDAQ:SAVA) stock is struggling to rebound. A long document written by the lawyer of a short-seller sent SAVA stock lower. The document challenged the accuracy of some of Cassava’s clinical results.
Cassava has two major clinical studies underway. The top-line data that it released on Sept. 22 is a positive turning point for the company.
The post This Stock is Rebounding appeared first on Trades Of The Day.